Indications |
Oral Thromboembolic disorders Adult: 4-12 mg on the 1st day and 4-8 mg on the 2nd day. Maintenance: 1-8 mg daily given in a single dose at the same time everyday. |
Contraindications |
Active haemorrhage or risk of serious haemorrhage; severe hypertension; pregnancy. |
Warnings / Precautions |
Bleeding disorders; peptic ulcers; severe wounds; cerebrovascular disorders, bacterial endocarditis; renal or hepatic impairment; lactation. Avoid alcohol. |
Adverse Reactions |
Alopecia; fever, nausea, vomiting, diarrhoea; skin rash; cholestatic liver damage. Potentially Fatal: Haemorrhage. |
Drug Interactions |
Potentiates hypoglycaemic agents. Bismuth carbonate and Mg reduce absorption. Cimetidine, allopurinol, diuretics and other oral anticoagulants enhance effect. vit K reverses effect. Potentially Fatal: Potentiated by NSAIDs, amiodarone, antibacterial agents eg, co-trimoxazole, cephalosporins, erythromycin, quinolone antibiotics, chloramphenicol, doxycycline, INH and neomycin. Rifampicin, barbiturates and griseofulvin diminish effect. See Below for More acenocoumarol Drug Interactions |
Food Interactions |
Renal excretion of metabolites is decreased when administered with grapefruit juice. |
Mechanism of Actions |
Acenocoumarol inhibits synthesis of vitamin K-dependent coagulation factors VII, IX, X and II including anticoagulant protein C and its cofactor proteins. Absorption: Readily absorbed from the GI tract. Distribution: Extensively bound to plasma proteins. Excretion: Largely in the urine mainly as metabolites. Elimination half-life: 8-11 hr. |
Storage Conditions |
Oral: Store at 20-25°C. |
ATC Classification |
B01AA07 - acenocoumarol ; Belongs to the class of vitamin K antagonists. Used in the treatment of thrombosis. |
Storage |
Oral: Store at 20-25°C. |
Available As |
|
Acenocoumarol
Post Review about Acenocoumarol Click here to cancel reply.
Acenocoumarol Containing Brands
Acenocoumarol is used in following diseases
Drug - Drug Interactions of Acenocoumarol
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.